GB1211

About Galecto

Galecto's mission is to develop transformative therapeutics for fibrosis, inflammation, and cancer by selectively inhibiting galectin proteins, central mediators of these disease processes. Its key achievement is advancing its lead oral galectin-3 inhibitor, GB1211, into Phase 2 trials for liver fibrosis and Phase 1b/2 for oncology combinations. The company's strategy is to generate robust clinical proof-of-concept data in these serious conditions to unlock significant value. Galecto operates as a focused, platform-based entity, aiming to demonstrate the broad therapeutic potential of its galectin-targeting approach.

About Galecto

Galecto's mission is to develop transformative therapeutics for fibrosis, inflammation, and cancer by selectively inhibiting galectin proteins, central mediators of these disease processes. Its key achievement is advancing its lead oral galectin-3 inhibitor, GB1211, into Phase 2 trials for liver fibrosis and Phase 1b/2 for oncology combinations. The company's strategy is to generate robust clinical proof-of-concept data in these serious conditions to unlock significant value. Galecto operates as a focused, platform-based entity, aiming to demonstrate the broad therapeutic potential of its galectin-targeting approach.

About Galecto

Galecto's mission is to develop transformative therapeutics for fibrosis, inflammation, and cancer by selectively inhibiting galectin proteins, central mediators of these disease processes. Its key achievement is advancing its lead oral galectin-3 inhibitor, GB1211, into Phase 2 trials for liver fibrosis and Phase 1b/2 for oncology combinations. The company's strategy is to generate robust clinical proof-of-concept data in these serious conditions to unlock significant value. Galecto operates as a focused, platform-based entity, aiming to demonstrate the broad therapeutic potential of its galectin-targeting approach.

Therapeutic Areas